Comparison of the IOP lowering effect of cataract surgery in combination with microinvasive glaucoma surgery (MIGS)

Session Details

Session Title: Glaucoma II

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 09:38

Venue: Hall C4

First Author: : M.Braun GERMANY

Co Author(s): :    G. Sauder                    

Abstract Details

Purpose:

We compared retrospective the IOP lowering effect of cataract surgery only, cataract surgery combined with the implantation of 2 iStent inject and cataract surgery combined with the endoscopic cyclophotocoagulation (ECP) of the ciliary body.

Setting:

Charlottenklinik für Augenheilkunde, Stuttgart, Germany

Methods:

The study included 116 eyes. 29 underwent cataract surgery only, 42 in combination with the implantation of 2 iStent inject and 45 in combination with the endoscopic cyclophotocoagulation of the ciliary body (ECP). Surgeries were performed by 5 experienced surgeons. The postoperative IOPs were measured by referring ophthalmologists in a 20 month follow up period. There were no significant statistical differences observed in gender and age. After statistical evaluation we added a literature described IOP lowering effect of the antiglaucoma drugs to any value.

Results:

The cataract surgery showed a reduction of the IOP of -0,86 % (10-12 months), after 13-15 months +0,43 %, the combination with iStent -9,62 % (10-12 months) and -10,31 % (13-15 months) and the combination with ECP -13,3 % (10-12 months) and -9,3 % (13-15 months). With the drug lowering effect, the cataract surgery only showed -21,98 % (10-12 months), -9,53 % (13-15 months), combination with iStent -25,54 % (10-12 months), -27,07 % (13-15 months) and in combination with ECP -14,38 % (10-12 months), -10,71 % (13-15 months).

Conclusions:

The results show an IOP reduction on the procedures combined with MIGS. An interesting finding is that the IOP decrease of the cataract surgery itself is seen by adding the reported lowering effect of the antiglaucoma drugs. To further verify the acuracy of these results, a prospective study with an absence period of the antiglaucoma drugs before IOP measuring is required.

Financial Disclosure:

NONE